The Effect of Cisplatin plus Etoposide Therapy on Serum Total and Lipid-Bound Sialic Acid Levels in Patients with Non-small Cell Lung Cancer

Basit Öğe Kaydı
dc.contributor.authorGokmen, Selma Suer
dc.contributor.authorKazezoglu, Cemal
dc.contributor.authorTabakoglu, Erhan
dc.contributor.authorGungor, Ozgul
dc.contributor.authorAltiay, Gundeniz
dc.contributor.authorTure, Mevlut
dc.date.accessioned2024-06-12T11:16:31Z
dc.date.available2024-06-12T11:16:31Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives: To investigate the effect of cisplatin+etoposide therapy on serum total and lipid-bound sialic acid levels in patients with non-small cell lung cancer and evaluate the role of these parameters in the monitoring of the therapy. Patients and Methods: To 18 patients (all men) who are newly diagnosed as nonsmall cell lung cancer, cisplatin was given intravenously (80mg/m(2)) on day 1 and etoposide was given (100mg/m(2)) on day 1-3 to the patients once at an interval of 21 day. Blood samples before the first chemotherapy were compared with those obtained after the second and third chemotherapy. The percent of chemotherapy responses of patients were also calculated. Total and lipid-bound sialic levels were determined by the methods of Warren and Katopodis, respectively. Results: There was a significant decrease in serum lipid-bound sialic acid levels after the second chemotherapy when compared with those before the first chemotherapy (t=2.216, p=0.041). Positive response to cisplatin+etoposide therapy was observed in 88.89% (11.11% of total response, 44.44% of partial response and 33.33% of stable response) of the patients. Progressive disease was established in only 11.11% of the patients. It was found a statistically significant decrease in both serum total (t=2.924, p=0.017) and lipid-bound sialic acid (t=3.635, p=0.005) levels after the third chemotherapy when compared with those before the first chemotherapy. Conclusion: Determination of serum total and lipid-bound sialic acid levels besides routine applications may be useful in the monitoring of cisplatin+etoposide therapy.en_US
dc.identifier.endpage242en_US
dc.identifier.issn0250-4685
dc.identifier.issue3en_US
dc.identifier.startpage236en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24352
dc.identifier.volume35en_US
dc.identifier.wosWOS:000282700000012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherTurkish Biochem Socen_US
dc.relation.ispartofTurkish Journal Of Biochemistry-Turk Biyokimya Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTotal Sialic Aciden_US
dc.subjectLipid-Bound Sialic Aciden_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectCisplatin Plus Etoposide Therapyen_US
dc.subjectB16f-10 Melanoma-Cellsen_US
dc.subjectAntimetastatic Activityen_US
dc.subjectMetastasisen_US
dc.subjectInhibitionen_US
dc.subjectTumoren_US
dc.subjectMiceen_US
dc.subjectCarcinogenesisen_US
dc.subjectExpressionen_US
dc.subjectCarcinomaen_US
dc.subjectSurfaceen_US
dc.titleThe Effect of Cisplatin plus Etoposide Therapy on Serum Total and Lipid-Bound Sialic Acid Levels in Patients with Non-small Cell Lung Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu